

**POLYPHASIC APPROACH TO UNDERSTAND THE DISTRIBUTION
AND DYNAMICS OF TEM β -LACTAMASE IN ENVIRONMENTAL
BACTERIAL POPULATIONS**

by

PRIYANKA GEHLOT



CENTRE FOR RURAL DEVELOPMENT AND TECHNOLOGY

INDIAN INSTITUTE OF TECHNOLOGY DELHI

JULY 2025

©Indian Institute of Technology Delhi (IITD), New Delhi, 2025

**POLYPHASIC APPROACH TO UNDERSTAND THE DISTRIBUTION
AND DYNAMICS OF TEM β -LACTAMASE IN ENVIRONMENTAL
BACTERIAL POPULATIONS**

by

PRIYANKA GEHLOT

CENTRE FOR RURAL DEVELOPMENT & TECHNOLOGY

submitted

in fulfilment of the requirements of degree of

Doctor of Philosophy

to the



INDIAN INSTITUTE OF TECHNOLOGY DELHI

JULY 2025

CERTIFICATE

This is to certify that the thesis **entitled** “*Polyphasic approach to understand the distribution and dynamics of TEM β -Lactamase in environmental bacterial populations*” being submitted by **Ms. Priyanka Gehlot** to the Indian Institute of Technology Delhi for the award of “**Doctor of Philosophy**” is a record of bonafide research work carried out by her. She has worked under my guidance and supervision and has fulfilled the requirements for submission of this thesis. To the best of my knowledge, the results contained in this thesis have not been submitted in part or full to any other university or institute for the award of any degree or diploma.

Prof. Hariprasad P.

Associate Professor

Centre for Rural Development & Technology

Indian Institute of Technology Delhi

New Delhi- 110016

ACKNOWLEDGMENT

"The roots of all goodness lie in the soil of appreciation for goodness." – Dalai Lama

First and foremost, I want to thank the *Almighty* & my *grandfathers* without their blessing and kindness this journey will be impossible. Their presence is a constant source of strength and motivation in my daily life, providing me with the courage to persevere.

I am forever grateful to my supervisor, *Prof. Hariprasad P.* for his invaluable guidance and support throughout my PhD. Thank you, sir, for believing in my potential and pushing me to excel even during the most challenging phases of this journey. Under your mentorship, I have learned the importance of ambition, focus, and resilience. Your encouragement and challenges have not only deepened my understanding of research but also imparted invaluable life lessons, teaching me that success requires sacrifices and patience.

I am profoundly grateful to the Director of the *Indian Institute of Technology Delhi* for providing all the necessary facilities to conduct this research work. It has been a great privilege to work at the *Centre for Rural Development and Technology (CRDT)*, Indian Institute of Technology, Delhi. I am grateful to my SRC members: *Prof. V.M. Charier, Prof. Satyawati Sharma, Prof. Anushree Malik* and *Prof. Ashok Patel* for providing valuable suggestions and informative ideas throughout the course of this research. I also would like to thank all the faculty members of CRDT for extending all the possible help in completing my thesis on time.

I would like to acknowledge the *Prime Minister Research Fellowship (PMRF:1400787)*, *Government of India* and *Council of Scientific & Industrial Research (CSIR)* India for providing fellowship to conduct the entire research smoothly. I am also grateful to the *Delhi Jal Board (DJB)*, *farmers and gaushalas owners* of Delhi-NCR for allowing us to collect the various STPs, agricultural soil, cow dung, biogas slurry and cow urine samples during the PhD.

I would like to acknowledge my seniors of Environmental Biotechnology Lab: *Dr. Shubhra Pande, Dr. Vasanth, Dr. Koushalya S, Dr. Vijallakshmi, Dr. Shazia Shareef, Dr. Leena Chauhan, Dr. Umesh, Dr. Duraivadivel, Dr. Gourav, Dr. Monu, Dr. Bhani Kongkham, Dr. Saiema Ahmed, Dr. Gunjan Kandpal and Kapil Choudary* for their guidance and support throughout this journey. I want to extend my warmest thanks to my junior colleagues: *Ajay Yadav, Shivangani, Sabia Luthra, Ankur Rana, Amar Kumar,*

Prerna Bhardwaj and *Subashree Mohanty* for providing truly joyful and pleasant experience.

I have been fortunate to form the purest bonds of friendship and sisterhood with *Imliasangla Aier, Lemnaro and N. Jaya Lakshmi*. Thank you for your constant support, understanding, and motivation during the most challenging times. From sharing PMRF TAs and work responsibilities to hostel routines, Amul coffee breaks, and summer lunches and dinners at the night mess, these moments will always hold a special place in my heart. The time spent with you all was truly the best part of my journey at IIT, and I will always be deeply grateful.

I am also thankful to *Mr. Hridyaram* and *Mrs. Pratibha Rana* for their help in the management of lab work. I also extend my gratitude to non-teaching staff of the institute, *Mrs. Joshi, Mr. Rajendar, Mr. Chopra, Mr. Gaurav, Mr. Shashank* and *Ms. Preeti* for helping me in handling and processing of my official documents.


The Journey of PhD would be incomplete without acknowledging the special people I meet in IIT Delhi: *Dr. Subodh Kumar, Ujjban Kataki, Shivangi Pathak, Srishthi Agarwal, Dr. Samridhi Rana, Tanuja Jayas, Achala Gupta, Pooja Tiwari, Sachin Bhujbal, Pinaki Das Gupta, Rajeev Kumar, Pratistha Kumari, Yash Jain, Gyan Datta Tripathi, Sateesh, Rahul Kumar, Sumit Dhali, Prasanna Kumaran, Dr. Amrita Preetam*, and all my well-wishers whom I may have forgotten to mention, thank you all for mine constant support system during this entire journey.

Finally, and most importantly, I would like to express my deepest gratitude and appreciation to my father: *Mr. Ashok Gehlot* and Mother: *Mrs. Saroj Gehlot*, my sister: *Ms. Kajal Gehlot*, and my brother: *Mr. Deepesh Gehlot*, who have been unwavering pillars of strength throughout this journey. Their love, understanding, and encouragement have been the driving force behind my academic and personal achievements. I also extend heartfelt thanks to my father-in-law, *Mr. Ramesh Yadav*, and my mother-in-law, *Mrs. Asha Yadav*, for their patience and understanding as I dedicated myself to completing this journey. My Ph. D. endeavour could not be completed without their endless love, unending support, and blessings.

Lastly, a special thanks to my best friend and now husband, *Mr. Pritam Yadav*, who has stood by me through every challenge, including the struggles of failed experiments. Your endorsement through this period is beyond words. I could not imagine completing this journey without your incredible support. Your constant motivation and unwavering belief in me have been my greatest source of strength. I am forever thankful to God for blessing me

with such a supportive and loving partner, whose presence has truly empowered me to overcome obstacles and reach new heights.

This thesis is a testament to the collective efforts, encouragement, and blessings of everyone who has been part of my journey. I am forever indebted to you all.

A handwritten signature in blue ink that reads "Behlot". The signature is written in a cursive style and is underlined with a single horizontal line.

Best wishes
Priyanka Gehlot

ABSTRACT

Antimicrobial resistance (AMR) is a global health threat, driven by multidrug-resistant (MDR) bacteria, including strains resistant to key drugs like carbapenems and colistin. Antibiotics have improved life expectancy and food security while their overuse in medicine, agriculture, and aquaculture practices has accelerated bacterial resistance in various environmental spheres across the globe. The emergences of β -lactam resistant bacteria (BLRB) especially carbapenem-resistant *Enterobacteriaceae* (CRE) designated as an urgent priority pathogen posing significant threats by infiltrating into water systems and food chains. Therefore, understanding and constantly monitoring BLRB and their genomic evolution in response to antibiotics and inhibitors, particularly to detect the emergence of novel mutants that may pose serious threats to both human and animal health. This study is crucial as India (largest antibiotic consumer) faces significant AMR risks, particularly in region with higher population density like Delhi. This research is the first comprehensive analysis of the environmental risks posed by BLRB along with their resistant genes in Delhi-National Capital Region (Delhi-NCR).

Among the various classes of β -lactamase enzymes, TEM-type β -lactamases are the most widely distributed and exhibit a high mutability rate, making them key contributors to the development of extended-spectrum and inhibitor-resistant β -lactamase variants that mediate bacterial resistance to β -lactam antibiotics. There are almost 474 variants of Temoneria (TEM) β -lactamase (BLs) identified in Lactamase Engineering Database (LacED). The first aim was to understand dynamics and distribution of TEM type β -Lactamase through Computational and Data Mining approach. The computational study results demonstrated that most TEM mutants recorded the least binding energy to penicillin and cephalosporin class of antibiotics and higher binding energy to carbapenem and monobactam class of antibiotics. Among the BLs inhibitors, tazobactam recorded the least binding energy against most of the TEM mutants, indicating that it can lower the catalytic activity of TEM BLs, thereby potentiating antibiotic action. Through the data mining approach TEM mutant database was generated, highlighting TEM mutations, bacterial diversity, Michaelis-Menten Constant's (K_m), Minimum inhibitory concentration (MIC), and Inhibitor resistant TEM (IRT) types. It has been noted that earlier released antibiotics like amoxicillin and ampicillin had lower K_m and higher MIC values, which indicates the prevalence of bacterial resistance. By analysing the differential binding energy (ΔBE) of the selected TEM mutants against β -lactam and BLs inhibitors, the most effective combination of β -lactam (carbapenem and monobactam class of antibiotics) and BLs inhibitors

(tazobactam) was identified, to cure bacterial diseases/infections and to prevent similar antibiotic resistance outbreaks in near future.

After understanding the dynamics and distributions of already reported TEM mutants, the second aim was to assess the prevalence and resistance characteristics of BLRB and β -lactamase resistant bacterial genes (BLRBG) under various environmental conditions within Delhi NCR, India. Using a culture-dependent method, isolated 130 BLRB from 75 different environmental samples, including lakes, ponds, the Yamuna River, agricultural soil, aquatic weeds, drains, dumping yards, sewage treatment plants (STPs) and gaushalas. Antibiotic susceptibility, phenotypic, and genotypic tests for β -lactamases and integron genes were conducted. Water and sediment samples of waterbodies was found to be substantial reservoir of BLRB and BLRBGs. The majority of the BLRB discovered are opportunistic pathogens from the *Bacillus*, *Aeromonas*, *Pseudomonas*, *Enterobacter*, *Escherichia* and *Klebsiella* genera, with Multiple Antibiotic Resistance (MAR) index ≥ 0.2 against a wide variety of β -lactams and β -lactamase inhibitor combinations. Interestingly, we discovered that 10 isolates of various origins produce both Extended Spectrum BLs and Metallo BLs, as well as found harbouring *blaTEM*, *blaCTX*, *blaOXA*, *blaSHV*, *int-1* and *int-3* genes.

Further, the third objective aimed to identify novel TEM mutant from isolated environmental BLRBs. For this 6 BLRBs were selected from the 10 BLRBs which has shown the presence of *blaTEM* gene in our second objective work. The minimum inhibitory concentration against the shortlisted 6 BLRBs showed that *Escherichia ruyisae*, *Pseudomonas aeruginosa* and *Bacillus* sp., have high MIC to the most of antibiotics and inhibitors combinations, indicating their highly resistance phenotype. To explore TEM mutant diversity, blunt end cloning, plasmid isolation and sequencing of the *blaTEM* gene was performed and found to harbour different TEM BLs mutants such TEM-142, 10, 22, 205 and novel TEM mutant, TEM(N) with multiple amino acid mutations at Met 55 Leu, Trp 151 Gly, Asn 255 Thr and Arg 256 Leu. Identified the TEM(N) mutant from *Escherichia ruyisae* isolated from the Sewage treatment plant of Okhla, New Delhi. The 3D structure of the novel TEM mutant was generated by Swiss protein modeller. Further, Molecular Dynamics (MD) Simulations were performed on the wildtype TEM-1 and TEM(N) to analysis the effect and interaction of mutating residues with the β -lactams and BLs inhibitors. *In-vitro* and MD analysis suggests that TEM(N) mutant resist to penicillin, cephalosporin and carbapenem classes, as well as to β -lactamase inhibitors like avibactam, tazobactam and relebactam, posing a significant public and environmental health threat. Our

study emphasizes the importance of surveillance which will monitor the emergence of novel BLRB and BLRG and will aid in predicting epidemics and devising appropriate preventive measures.

सार

रोगाणुरोधी प्रतिरोध (एएमआर) एक वैश्विक स्वास्थ्य खतरा है, जो बहुऔषधि प्रतिरोधी (एमडीआर) बैक्टीरिया द्वारा संचालित होता है, जिसमें कार्बापेनम और कोलिस्टिन जैसी प्रमुख दवाओं के प्रतिरोधी उपभेद शामिल हैं। एंटीबायोटिक्स ने जीवन प्रत्याशा और खाद्य सुरक्षा में सुधार किया है, जबकि चिकित्सा, कृषि और जलीय कृषि प्रथाओं में उनके अत्यधिक उपयोग ने दुनिया भर में विभिन्न पर्यावरणीय क्षेत्रों में जीवाणु प्रतिरोध को तेज कर दिया है। बीटा-लैक्टम प्रतिरोधी बैक्टीरिया (बीएलआरबी) विशेष रूप से कार्बापेनम प्रतिरोधी एंटरोबैक्टीरिया (सीआरई) का उद्भव एक तत्काल प्राथमिकता वाले रोगजनक के रूप में नामित किया गया है जो जल प्रणालियों और खाद्य श्रृंखलाओं में घुसपैठ करके महत्वपूर्ण खतरे पैदा कर रहा है। इसलिए, एंटीबायोटिक्स और अवरोधकों के जवाब में बीएलआरबी और उनके जीनोमिक विकास को समझना और लगातार निगरानी करना, विशेष रूप से नए म्यूटेंट के उद्भव का पता लगाना जो मानव और पशु स्वास्थ्य दोनों के लिए गंभीर खतरे पैदा कर सकते हैं। यह अध्ययन महत्वपूर्ण है क्योंकि भारत (सबसे बड़ा एंटीबायोटिक उपभोक्ता) महत्वपूर्ण एएमआर जोखिमों का सामना करता है, खासकर दिल्ली जैसे उच्च जनसंख्या घनत्व वाले क्षेत्र में। यह शोध दिल्ली-राष्ट्रीय राजधानी क्षेत्र (दिल्ली-एनसीआर) में बीएलआरबी के साथ-साथ उनके प्रतिरोधी जीनों द्वारा उत्पन्न पर्यावरणीय जोखिमों का पहला व्यापक विश्लेषण है।

β -लैक्टम एंटीबायोटिक दवाओं के खिलाफ बैक्टीरिया का प्रतिरोध मुख्य रूप से टेमोनेरिया (टीईएम) β -लैक्टामेज (बीएल) के उत्पादन के माध्यम से होता है, जिसमें लैक्टामेज इंजीनियरिंग डेटाबेस (एलएसीईडी) में लगभग 474 वेरिएंट की पहचान की गई है। पहला उद्देश्य कम्प्यूटेशनल और डेटा माइनिंग दृष्टिकोण के माध्यम से टीईएम प्रकार β -लैक्टामेज की गतिशीलता और वितरण को समझना था। कम्प्यूटेशनल अध्ययन के परिणामों ने प्रदर्शित किया कि अधिकांश टीईएम म्यूटेंट ने पेनिसिलिन और सेफलोस्पोरिन वर्ग के एंटीबायोटिक दवाओं के लिए सबसे कम बंधन ऊर्जा और कार्बापेनम और मोनोबैक्टम वर्ग के एंटीबायोटिक दवाओं के लिए उच्च बंधन ऊर्जा दर्ज की डेटा माइनिंग दृष्टिकोण के माध्यम से TEM म्यूटेंट डेटाबेस तैयार किया गया, जिसमें TEM म्यूटेशन, बैक्टीरियल विविधता, माइकेलिस-मेन्टेन कॉन्स्टेंट (K_m), न्यूनतम अवरोधक सांद्रता (MIC), और अवरोधक प्रतिरोधी TEM (IRT) प्रकारों पर प्रकाश डाला गया। यह देखा गया है कि पहले जारी किए गए एंटीबायोटिक्स जैसे एमोक्सिसिलिन और एम्पीसिलीन में K_m कम और MIC मान अधिक थे, जो बैक्टीरिया प्रतिरोध की व्यापकता को दर्शाता है। β -लैक्टम और BLs अवरोधकों के खिलाफ चयनित TEM म्यूटेंट की अंतर बंधन ऊर्जा (ΔBE) का विश्लेषण करके, बैक्टीरियल रोगों/संक्रमणों को ठीक करने और निकट भविष्य में इसी तरह के एंटीबायोटिक प्रतिरोध प्रकोपों को रोकने के लिए β -लैक्टम (कार्बापेनम और

मोनोबैक्टम एंटीबायोटिक्स का वर्ग) और BLs अवरोधकों (टैज़ोबैक्टम) का सबसे प्रभावी संयोजन पहचाना गया। पहले से रिपोर्ट किए गए TEM म्यूटेंट की गतिशीलता और वितरण को समझने के बाद, दूसरा उद्देश्य भारत के दिल्ली एनसीआर में विभिन्न पर्यावरणीय परिस्थितियों में BLRB और β -लैक्टामेस प्रतिरोधी जीवाणु जीन (BLRBG) की व्यापकता और प्रतिरोध विशेषताओं का आकलन करना था। संस्कृति-निर्भर विधि का उपयोग करते हुए, झीलों, तालाबों, यमुना नदी, कृषि मिट्टी, जलीय खरपतवार, नालों, डंपिंग यार्ड, सीवेज ट्रीटमेंट प्लांट (STP) और गौशालाओं सहित 75 विभिन्न पर्यावरणीय नमूनों से 130 BLRB को अलग किया गया। β -लैक्टामेस और इंटेग्रोन जीन के लिए एंटीबायोटिक संवेदनशीलता, फेनोटाइपिक और जीनोटाइपिक परीक्षण किए गए। जल निकायों के पानी और तलछट के नमूनों में BLRB और BLRBGs का पर्याप्त भंडार पाया गया। खोजे गए BLRB में से अधिकांश बैसिलस, एरोमोनस, स्यूडोमोनस, एंटरोबैक्टर, एस्चेरिचिया और क्लेबसिएला जेनेरा से अवसरवादी रोगजनक हैं, जिनमें कई प्रकार के β -लैक्टम और β -लैक्टामेज अवरोधक संयोजनों के खिलाफ मल्टीपल एंटीबायोटिक प्रतिरोध (MAR) सूचकांक ≥ 0.2 है। दिलचस्प बात यह है कि हमने पाया कि विभिन्न मूल के 10 आइसोलेट्स विस्तारित स्पेक्ट्रम BLs और मेटालो BLs दोनों का उत्पादन करते हैं, साथ ही blaTEM, blaCTX, blaOXA, blaSHV, int-1 और int-3 जीन को आश्रय देते हैं। इसके अलावा, तीसरे उद्देश्य का उद्देश्य पृथक पर्यावरणीय BLRBs से नए TEM उत्परिवर्ती की पहचान करना था। इसके लिए 10 BLRBs में से 6 BLRBs का चयन किया गया, जिसने हमारे दूसरे उद्देश्य कार्य में blaTEM जीन की उपस्थिति को दर्शाया है। शॉर्टलिस्ट किए गए 6 BLRBs के खिलाफ न्यूनतम निरोधात्मक सांद्रता ने दिखाया कि एस्चेरिचिया रुइसिया, स्यूडोमोनस एरुगिनोसा और बैसिलस एसपी. में अधिकांश एंटीबायोटिक्स और अवरोधक संयोजनों के लिए उच्च MIC है, जो उनके अत्यधिक प्रतिरोधी फेनोटाइप को दर्शाता है। TEM उत्परिवर्ती विविधता का पता लगाने के लिए, ब्लंट एंड क्लोनिंग, प्लास्मिड अलगाव और blaTEM जीन की अनुक्रमण किया गया और पाया गया कि इसमें विभिन्न TEM BLs उत्परिवर्ती जैसे TEM-142, 10, 22, 205 और नए TEM उत्परिवर्ती, TEM(N) में कई अमीनो एसिड उत्परिवर्तन हैं जो Met 55 Leu, Trp 151 Gly, Asn 255 Thr और Arg 256 Leu पर हैं। नई दिल्ली के ओखला के सीवेज उपचार संयंत्र से अलग किए गए Escherichia ruysiae से TEM(N) उत्परिवर्ती की पहचान की गई। स्विस प्रोटीन मॉडेलर द्वारा नए TEM उत्परिवर्ती की 3D संरचना तैयार की गई। इसके अलावा, β -लैक्टम और BLs अवरोधकों के साथ उत्परिवर्तित अवशेषों के प्रभाव और अंतःक्रिया का विश्लेषण करने के लिए वाइल्डटाइप TEM-1 और TEM(N) पर आणविक गतिशीलता (MD) सिमुलेशन किए गए। इन-विट्रो और एमडी विश्लेषण से पता चलता है कि टीईएम (एन) म्यूटेंट पेनिसिलिन, सेफलोस्पोरिन और कार्बापेनम वर्गों के साथ-साथ एविबैक्टम,

टैज़ोबैक्टम और रिलेबैक्टम जैसे बीटा-लैक्टामेज अवरोधकों का प्रतिरोध करता है, जो एक महत्वपूर्ण सार्वजनिक और पर्यावरणीय स्वास्थ्य खतरा पैदा करता है। हमारा अध्ययन निगरानी के महत्व पर जोर देता है जो नए बीएलआरबी और बीएलआरजी के उद्भव की निगरानी करेगा और महामारी की भविष्यवाणी करने और उचित निवारक उपाय तैयार करने में सहायता करेगा।

TABLE OF CONTENTS

Sr. no	Contents	Page no
1	Certificate	i
2	Acknowledgement	ii-iv
3	Abstract	v-x
4	Table of Content	xi-xiv
5	List of Figures	xv-xxii
6	List of Tables	xxiii
7	List of Abbreviations	xxiv-xxv
8	Chapter 1: Introduction 1.1. Antibiotics 1.2. Global pattern of antibiotic consumption 1.3. β -lactam: The most commonly used antibiotic 1.3.1. Origin and diversification of β -lactam antibiotics 1.3.2. Mechanism of action of β -lactam antibiotics to inhibit cell wall synthesis 1.4. Dissemination of antibiotics and emergence of antibiotic-resistant bacteria in environmental settlements 1.5. Different resistance mechanism developed by the bacterial communities 1.6. β -lactamase 1.6.1. Classification of β -lactamase 1.6.1.1. Serine β -lactamase 1.6.1.2. Metallo- β -Lactamase β -lactamase 1.7. β -lactamase Inhibitor 1.8. Emergence of extended spectrum β -lactamase	1-19
9	Chapter 2: Review of Literature 2.1. Status of environmental β -lactam resistant bacteria and β -lactamase resistant genes studies across the globe 2.2. Status of environmental β -lactam resistant bacteria and β -lactamase resistant genes studies in India 2.3. TEM Type β -lactamase 2.4. Regional and bacterial distribution of TEM β -lactamase protein 2.5. Evolution of TEM β -lactamase mutants	20-36

	<p>2.6. Emergence of inhibitor resistant TEM type β-lactamase</p> <p>2.7. Impact of COVID-19 on the Environmental Dynamics of blaTEM Gene Dissemination</p> <p>2.8. Significance of TEM Surveillance in Delhi-NCR, India</p> <p>2.9. Research gaps</p> <p>2.10. Research objectives</p> <p>2.11. Structure and Rationale of Objectives</p>	
10	<p>Chapter 3: Computational and Data Mining approach to understand dynamics and distribution of TEM type β-Lactamase</p> <p>3.1. Introduction</p> <p>3.2. Material and Methods</p> <p>3.2.1. Preparation of TEM β-Lactamase mutant library</p> <p>3.2.2. Preparation of ligands (β-lactam antibiotics and BLs inhibitors)</p> <p>3.2.3. Preparation of wild-type TEM-1 β-Lactamase and mutant's validation</p> <p>3.2.4. Molecular docking and data analysis</p> <p>3.2.5. Data Mining Studies</p> <p>3.3. Result and Discussion</p> <p>3.3.1. In silico analysis of structural variations among TEM mutant and their impact on β-lactam and β-Lactamase inhibitors affinities</p> <p>3.3.2. Data Mining result analysis</p> <p>3.3.3. Predicting the effective combination of β-lactam β-lactamase inhibitors using molecular docking results</p> <p>3.4. Conclusion</p>	37-63
11	<p>Chapter 4: Profiling β-lactam and inhibitor resistant/ susceptible pattern in bacteria isolated from different environmental settlings across the Delhi-NCR</p> <p>4.1. Introduction</p> <p>4.2. Material and Methods</p> <p>4.2.1. Collection of environmental samples across the Delhi National Capital Region</p> <p>4.2.2. Isolation of β-lactam-resistant bacteria</p> <p>4.2.3. Detection of β-lactamase production: Nitrocefin Assay</p>	64-105

	<p>4.2.4. Resistance/susceptibility patterns analysis of bacteria against the β-lactam antibiotics and β-lactam β-Lactamase inhibitor combinations</p> <p>4.2.5. Phenotypic characterization of bacterial β-Lactamase</p> <p>4.2.5.1. Extended Spectrum β-Lactamase</p> <p>4.2.5.2. Metallo- β-Lactamase</p> <p>4.2.6. Molecular identification of bacterial isolates</p> <p>4.2.7. Genotypic detection of β-Lactamase genes and integrons carrying isolates</p> <p>4.2.8. Data Analysis</p> <p>4.3. Result and Discussion</p> <p>4.3.1. Bacterial isolates across Delhi-NCR region recorded diverse antibiotic resistance patterns</p> <p>4.3.1.1. High abundance of bacteria in different environmental settings</p> <p>4.3.1.2. Molecular identification revealed the bacterial heterogeneity in environmental samples</p> <p>4.3.1.3. Clustering analysis of resistance profile showed random distribution of BLRBs in different environmental settings</p> <p>4.3.2. Environmental bacterial isolates recorded diversification in β-Lactamase type</p> <p>4.3.3. Prevalence and wide diversification of β-Lactamase and Integrons genes in β-lactam resistant bacteria</p> <p>4.3.4. Networking analysis revealed the complex interactions</p> <p>4.4. Conclusion</p>	
<p>12</p>	<p>Chapter 5: Identification and in-silico characterization of newly emerged novel TEM β- lactamase mutant from the environmental samples</p> <p>5.1. Introduction</p> <p>5.2. Material and Methods</p> <p>5.2.1. Selection of TEM β-Lactamase positive β-Lactam resistant bacteria isolated from different environmental settings of Delhi-NCR</p> <p>5.2.2. Determination of Minimum Inhibitory Concentration of β-Lactam antibiotics and β-Lactamase Inhibitors Combinations against β-Lactam resistant bacteria</p> <p>5.2.3. Extraction of genomic DNA and amplification of <i>blaTEM</i> gene harbored by BLRB</p>	<p>106-162</p>

	<p>5.2.4. Sequence analysis and detection of TEM mutants</p> <p>5.2.4.1. Cloning, transformation and extraction of plasmid from the <i>E. coli DH5α</i> strain with <i>blaTEM</i> gene</p> <p>5.2.4.2. Analysis of <i>blaTEM</i> gene sequence</p> <p>5.2.5. <i>In-silico</i> characterisation of novel TEM mutant</p> <p>5.2.5.1. Molecular docking studies</p> <p>5.2.5.2. Molecular dynamics simulations</p> <p>5.3. Result and Discussion</p> <p>5.3.1. Bacterial isolates across Delhi-NCR region exhibited wide diversity in <i>bla</i> and integrons genes along with <i>blaTEM</i> gene</p> <p>5.3.2. Wide variation in MIC values of different β-Lactam antibiotics and β-Lactamase Inhibitors combinations was recorded against the environmental β-Lactam resistant bacteria</p> <p>5.3.3. Molecular identification revealed the emergence of novel TEM β-Lactam resistant bacteria mutant from environmental β-Lactam resistant bacteria</p> <p>5.3.4. Computational studies revealed differential capabilities of TEM(N) to bind on β-lactam and β-Lactamase inhibitors compared to wildtype TEM-1 protein</p> <p>5.4. Conclusion</p>	
13	Chapter 6: Summary and Future Scope	163-166
14	References	167-195
15	Biodata	196-206

LIST OF FIGURES

Figure No.	Title of the Figure	Page No.
Fig. 1.1.	The mode of actions of different classes of antibiotics on bacterial cell.	3
Fig. 1.2.	(A) The total rate of antibiotic consumption in terms of DDD/1000 inhabitants per day and Metric Tonnes across the globe. (B) Percentage consumption of the different pharmacological subgroups of antibiotics.	5
Fig. 1.3.	Basic Structures of β -lactam antibiotics	7
Fig. 1.4.	Mechanism of action of β -lactam antibiotics that inhibit cell wall synthesis.	9
Fig. 1.5.	The general mechanisms of antibiotic resistance developed by the bacteria against the action of antibiotics.	12
Fig. 1.6.	Updated functional and molecular classification scheme of β -lactamase enzymes.	14
Fig. 1.7.	Penicillin hydrolysis mechanism by Serine β -lactamase.	15
Fig. 1.8.	Carbapenem hydrolysis mechanism by Metallo- β -lactamase.	18
Fig. 2.1.	Structure of TEM-1 β -lactamase enzyme.	24
Fig. 2.2.	(A) Regional distribution of TEM β -Lactamase across the globe. (B) Distribution of TEM β -Lactamase among the bacterial population.	26
Fig. 3.1.	Structures of the most commonly used β -lactam antibiotics of all classes and generations.	42
Fig. 3.2.	Structures of most commonly used β -lactamase inhibitors.	43
Fig. 3.3.	Ramachandran plot of the developed TEM mutant models. The most favoured regions are coloured red; additional allowed, generously allowed and disallowed regions are shown as yellow, light yellow and white fields, respectively.	46
Fig. 3.4.	Root mean square deviation (RMSD) of various TEM mutant models determined through PyMOL.	46
Fig. 3.5.	The stability prediction of TEM mutant models based on the change in Gibbs Free Energy (Kcal/mol) determined by using DynaMUT 2 Server.	47
Fig. 3.6.	(A) 3-D Interaction of ampicillin with the wild type TEM-1 protein (visualized in PyMOL).	47

	(B) 2-D Interaction of ampicillin with the wild type TEM-1 protein (visualized in Discovery studio)	
Fig. 3.7.	(A) 3-D Interaction of Relebactam with the wild type TEM-1 protein (visualized in PyMOL). (B) 2-D Interaction of Relebactam with the wild type TEM-1 protein (visualized in Discovery studio)	48
Fig. 3.8.	(A). Clustered Heat Map representing BE recorded by various TEM mutants. (B) Violin graph representing the distribution of TEM mutants according to their difference in BE with respect to wild type.	50
Fig. 3.9.	(a). Clustered Heat Map representing BE recorded by various TEM mutants. (b) Violin graph representing the distribution of TEM mutants according to their difference in BE with respect to wild type.	52
Fig. 3.10.	Relative occurrence of bacterial species recorded in data mining table to harbour different TEM mutants. Letters inside the parenthesis represent the keywords for bacterial species.	53
Fig. 3.11.	Michaelis-Menten Constant's (Km) variations were recorded for various TEM mutants against the β -lactam antibiotics. Here, the box represents 25 to 75% of the sample range (interquartile range). The horizontal line in the box represents the median line, the square point within the box is the mean, whiskers represent the 1.5 times of interquartile range and the points outside the box represents the outliers. The “P, C-I, C-II, C-III, C-IV, *C and M” represents penicillin, 1st,2nd, 3rd and 4th generation Cephalosporin, Cephalosporin substrate and Monobactam classes of β -lactam antibiotics, respectively. On the X-axis, “n” denotes the number of samples. Similarly, the 1st digit in parenthesis represents the minimum Km value of the respective antibiotic, followed by the type of TEM mutant and the bacterial species from which TEM mutants were isolated	55
Fig. 3.12.	The variations in minimum inhibitory concentration (MIC) value of different β -lactam antibiotics were recorded against the various TEM mutants. Here the box represents 25 to 75% of the sample range (interquartile range), the horizontal line in the box represents the median line, the square point within the box is the mean, whiskers represent the 1.5 times of interquartile range, and the points outside the box represents the outliers. The “P, C-I, C-II, C-III, C-IV and M” represents penicillin, 1st,2nd, 3rd and 4th generation Cephalosporin and	57

	Monobactam classes of β -lactam antibiotics, respectively. On X-axis, “n” denotes the number of samples. Similarly, the 1st digit in parenthesis represents the highest MIC value of the respective antibiotic, followed by the type of TEM mutant and the bacterial species from which TEM mutants were isolated.	
Fig. 3.13.	Heat maps representing differential binding affinity of selected TEM mutants reported to cause major outbreaks {(a) TEM-10, (b) TEM-24, (c) TEM-26 and (d) TEM-52} against β -lactam antibiotics and BLs inhibitors combinations.	60
Fig. 3.14.	Heat maps representing differential binding affinity of selected recently reported TEM mutants {(a) TEM-1, (b) TEM-116, (c) TEM-135 and (d) TEM-184} against β -lactam antibiotics and BLs inhibitors combinations.	61
Fig. 4.1.	Collection of samples across Delhi and surrounding area	68
Fig. 4.2.	Isolation of β -lactam resistant bacteria on Nutrient Agar plate from environmental samples.	70
Fig. 4.3.	Pure cultures of β -Lactam resistant bacterial isolates.	71
Fig. 4.4.	Gel electrophoresis of 16S rRNA gene amplified product on 1% agarose gel.	74
Fig. 4.5.	Gel electrophoresis of multiplex PCR product on 1% gel electrophoresis: (a) Integrons genes (b) β -lactamase genes.	75
Fig. 4.6.	Schematics representation of different sampling sites and sample types collected across Delhi-NCR. The colour intensity ranges from 0% to 93% is calculated based on the percent of resistant bacteria isolated from the samples.	79
Fig. 4.7.	Bar graph representing total bacterial count and ampicillin resistant bacterial count in different sampling sites. YR: Yamuna River, STPs: Sewage treatment plants, D: Drains, G: Gaushala, WB: Water Bodies (Lakes, Ponds and Swamps samples), DY: Dumping yard, S: Soil, AW: Aquatic weeds. Values in brackets on x axis represents the number of samples collected. *CFU/g in solid samples and CFU/mL in liquid samples.	80
Fig. 4.8.	(A) β -lactamase assay conducted in the microtitre plate (Yellow color of nitrocefin converted to Red color indicates the presence of enzyme). (B) Distribution histograms representing the β -lactamase activity in antibiotic-resistant bacterial isolates through Nitrocefin assay.	80
Fig. 4.9.	Circular representation of Phylogenetics Tree based on the maximum likelihood generated using 16S rRNA gene sequence of 130 bacteria. Colour dots represent the type of sample from which bacteria has been isolated.	83

Fig. 4.10.	(A) Representation of Disc diffusion plates. 1 and 2. plates embedded with β -lactam antibiotics discs of different generations and classes on NA plates, 3. β -lactam antibiotics and β -lactamase inhibitors combination discs embedded on NA plate. (B) Detection of ESBL (c) MBL enzyme-producing antibiotic-resistant bacteria. C* denotes empty sterile disc.	87
Fig. 4.11.	Clustered heat map representing the resistance/ susceptibility profile of β -lactam and BLs inhibitors combinations in bacterial isolates. The red shade in clustered heat map represents resistance phenotype while the green shade represents susceptible phenotype and the white shade as intermediate phenotype. P: Penicillin-G, CZ: Cefazolin, AMP: Ampicillin, IMP: Imipenem, CEP: Cephalothin, AT: Aztreonam, CZX: Ceftizoxime, CX: Cefoxitin, PI: Piperacillin, PIT: Piperacillin-Tazobactam, CXM: Cefuroxime, TCC: Ticarcillin- Clavulanic acid, CAZ: Ceftazidime, CPM: Cefepime, A/S: Ampicillin-Sulbactam, TI: Ticarcillin and CAC: Ceftazidime- Clavulanic acid.	88
Fig. 4.12.	(A). Heat map representing the resistance patterns observed in different environmental sample type across Delhi-NCR, India. (B). Box Plot representing the breakdown of MAR index across the different sample types to elucidate spatial variations in antibiotic resistance patterns. Here, n: Number of bacteria isolated, P: Penicillin-G, CZ: Cefazolin, AMP: Ampicillin, IMP: Imipenem, CEP: Cephalothin, AT: Aztreonam, CZX: Ceftizoxime, CX: Cefoxitin, PI: Piperacillin, PIT: Piperacillin-Tazobactam, CXM: Cefuroxime, TCC: Ticarcillin- Clavulanic acid, CAZ: Ceftazidime, CPM: Cefepime, A/S: Ampicillin-Sulbactam, TI: Ticarcillin and CAC: Ceftazidime- Clavulanic acid.	89
Fig. 4.13.	(A) The principal component of analysis indicates the distribution of antibiotic resistance/ susceptible bacteria according to sampling sites. (B) The principal component of analysis indicates antibiotic resistance/susceptibility profile of bacteria according to their genera. Here C1, C2, C3 and C4 represents the different clusters.	90
Fig. 4.14.	Venn diagram representing the types of β -Lactamase (BLs) produced by environmental isolates.	100

Fig. 4.15.	Clustered Heat map representing the diversity of different BLs and Integrons genes harbored by the environmental isolates. The red shades indicate the presence of gene and cyan shade shows the absence of gene in the isolates.	102
Fig. 4.16.	Network analysis of sampling source, types of BLs enzymes produced, expression of BLs genes and Integrons genes among environmental bacteria. The different abbreviations used are W.B- Water bodies, G-Gaushala, S-Soil, Y.R – Yamuna River, STP- Sewage Treatment Plant, A.W-Aquatic weed, D- Drainage, D.Y- Dumping yard, N-ESBL-Non-Extended spectrum BLs, ESBL-Extended spectrum BLs, MBL-Metallo-BLs, SBL-Serine BLs.	104
Fig. 5.1.	Schematic representation of sampling sites and types for the selected 6 TEM positive BLRBs on Delhi-NCR map.	117
Fig. 5.2.	<p>(A) Determination of minimum inhibitory concentration of different β-Lactam antibiotics and β-Lactamase Inhibitors (BLIs) through standard E-strip assay against <i>Bacillus paramycoides</i>. Note: (a) Ampicillin, (b) Amoxicillin (c) Cephalothin, (d) Ceftazidime, (e) Cefepime, (f) Imipenem, (g) Amoxycylav, (h) Ampicillin/Sulbactam, (i) Ceftazidime/Avibactam, (j) Ceftizoxime/Sulbactam, (k) Cefepime/Tazobactam and (l) Cefpirome/Sulbactam MIC strips.</p> <p>(B) Determination of minimum inhibitory concentration of different β-Lactam antibiotics and β-Lactamase Inhibitors (BLIs) through standard E-strip assay against <i>Pseudomonas aeruginosa</i>. Note: (a) Penicillin-G, (b) Ampicillin, (c) Cephalothin, (d) Imipenem, (e) Meropenem, (f) Ceftazidime, (g) Cefpirome/sulbactam, (h) Cefepime, (i) Piperacillin, (j) Cefepime/tazobactam, (k) Aztreonam and (l) Ceftazidime/Avibactam MIC strips.</p> <p>(C) Determination of minimum inhibitory concentration of different β-Lactam antibiotics and β-Lactamase Inhibitors (BLIs) through standard E-strip assay against <i>Bacillus cereus</i>. Note: (a) Amoxicillin, (b) Ampicillin, (c) Cephalothin, (d) Cefpirome, (e) Cefoxitin, (f) Cefazolin, (g) Cefotaxime, (h) Aztreonam, (i) Imipenem, (j) Ceftizoxime/Sulbactam, (k) Ceftazidime/Avibactam and (l) Cefixime/Clavulanic acid MIC strips.</p> <p>(D) Determination of minimum inhibitory concentration of different β-Lactam antibiotics and β-Lactamase Inhibitors (BLIs) through standard</p>	120- 125

	<p>E-strip assay against <i>Escherichia coli</i>. Note: (a) Amoxicillin, (b) Penicillin-G, (c) Ampicillin, (d) Cefuroxime, (e) Ceftazidime, (f) Cefpirome, (g) Cefepime, (h) Aztreonam, (i) Imipenem, (j) Ticarcillin/Clavulanic Acid, (k) Cefixime/Clavulanic acid and (l) Ceftizoxime/Sulbactam MIC strips.</p> <p>(E) Determination of minimum inhibitory concentration of different β-Lactam antibiotics and β-Lactamase Inhibitors (BLIs) through standard E-strip assay against <i>Escherichia ruysiae</i>. Note: (a) Ampicillin, (b) Cefuroxime, (c) Cephalothin, (d) Ceftazidime, (e) Imipenem, (f) Meropenem, (g) Cefepime, (h) Cefpirome, (i) Ticarcillin/Clavulanic Acid, (j) Cefixime/Clavulanic acid, (k) Amoxyclav and (l) Ceftizoxime/Sulbactam MIC strips.</p> <p>(F) Determination of minimum inhibitory concentration of different β-Lactam antibiotics and β-Lactamase Inhibitors (BLIs) through standard E-strip assay against <i>Bacillus sp.</i> (a) Ampicillin, (b) Amoxicillin (c) Cephalothin, (d) Ceftazidime, (e) Cefepime, (f) Imipenem, (g) Amoxyclav, (h) Ampicillin/Sulbactam, (i) Ceftazidime/Avibactam, (j) Ceftizoxime/Sulbactam, (k) Cefepime/Tazobactam and (l) Cefpirome/Sulbactam MIC strips.</p>	
Fig. 5.3.	Heat map representing MIC ($\mu\text{g}/\text{mL}$) of selective BLRBs against the various β -lactam antibiotics and BLs inhibitors combination. Here P: Penicillin class, C-I: First generation cephalosporin, C-II: Second generation cephalosporin, C-III: Third generation cephalosporin, C-IV: Fourth generation cephalosporin, C: Carbapenem class, M: Monobactam and BL+BLI: β -lactam + BLs Inhibitor Combination.	126
Fig. 5.4.	Multiple alignment of novel TEM (N) mutant protein sequence with wildtype TEM-1 protein (PDB: 4OQG).	129
Fig. 5.5.	(A) 3D and (B) zoom-out structure of wildtype TEM-1 BLs enzyme (PDB ID: 4OQG) with the highlighted AARs in sticks form. (C) 3D and (D) zoom-out structure of novel TEM (N) mutant protein with the highlighted AARs in stick form along with mutated residues (Met69Leu, Trp165Gly, Asn276Thr and Arg277Leu) in cyan stick form.	130

Fig. 5.6.	The Ramachandran plot for TEM (N) BLs modelled structure (1ZG4) using the PSVS server.	131
Fig. 5.7.	The variation in binding energies (kJ/mol) of wildtype and mutant TEM proteins against the antibiotics and BLs inhibitors.	133
Fig. 5.8.	(1) The variation in root means square deviation (RMSD) recorded for various wildtype TEM protein complexes with β -lactam antibiotics (A, B, C, D) and BLs inhibitors (E). (2) The variation in root means square deviation (RMSD) recorded for various novel TEM (N) mutant complexes with β -lactam antibiotics (A, B, C, D) and BLs inhibitors (E).	135- 136
Fig. 5.9.	(1) The variation in root means square fluctuations (RMSF) recorded for various wildtype TEM protein complexes with β -lactam antibiotics (A, B, C, D) and BLs inhibitors (E). (2) The variation in root means square fluctuations (RMSF) recorded for various novel TEM (N) mutant complexes with β -lactam antibiotics (A, B, C, D) and BLs inhibitors (E).	137- 138
Fig. 5.10.	(1) The variation in radius of gyration (Rg) recorded for various (1) wildtype TEM protein complexes with β -lactam antibiotics (A, B, C, D) and BLs inhibitors (E). (2) The variation in radius of gyration (Rg) recorded for various novel TEM (N) mutant complexes with β -lactam antibiotics (A, B, C, D) and BLs inhibitors (E).	139- 140
Fig. 5.11.	(1) The variation in solvent accessible surface area (SASA) recorded for various wildtype TEM protein complexes with β -lactam antibiotics (A, B, C, D) and BLs inhibitors (E). (2) The variation in solvent accessible surface area (SASA) recorded for various novel TEM (N) mutant complexes with β -lactam antibiotics (A, B, C, D) and BLs inhibitors (E).	141- 142
Fig. 5.12.	The variation in binding energies (kJ/mol) of wildtype and mutant TEM proteins against the antibiotics and BLs inhibitors were calculated using MMPBSA during the last 10 ns of simulation.	144
Fig. 5.13.	Snapshots of Protein-ligand interactions captured at 0, 60, 100 ns and visualised in PyMol software. Colour code: Protein (Green cartoon), Ligand (Stick magenta), active sites residues: S70 (Stick red), K73 (Stick orange), S130 (Stick	145- 155

	Blue), E166 (Stick yellow), K234 (Sticks Cyan) and Hydrogen bonds in Black dash lines	
Fig. 5.14.	Clustered heat map of H-bond occupancy (HBO) recorded during the last 10 ns of 100 ns simulation for (A) Wildtype TEM-1 complexes (B) Novel TEM (N) mutant complexes with β -lactam antibiotics and BL inhibitors.	158
Fig. 5.15.	(1) The variation in the number of Hydrogen bonds (HBN) formed throughout the 100 ns MD simulation run for wildtype TEM protein with β -lactam antibiotics (A, B, C, D) and BLs inhibitors (E). (2) The variation in the number of Hydrogen bonds (HBN) formed throughout the 100 ns MD simulation run for novel TEM (N) mutant with β -lactam antibiotics (A, B, C, D) and BLs inhibitors (E).	160- 161

LIST OF TABLES

Table No.	Title of Table	Page No.
Table 1.1.	List of commercially available β -lactamase inhibitors	17
Table 2.1.	Summary of Key Global and Indian Studies (2020–2025) on Environmental Detection of β -Lactamases (TEM BLs)	30-33
Table 4.1.	Details of the primers used in the study	77
Table 4.2.	Details informations of isolated 130 β -lactam resistant bacteria	91-97
Table 5.1.	Details of the <i>blaTEM</i> primers used in study	110
Table 5.2.	List of the Ligands used in the study	113
Table 5.3.	The detail information of the TEM mutants isolated from the different environmental BLRBs	128
Table 5.4.	Quality parameters of 3D modelled structure of novel TEM (N) mutant BLs	132

LIST OF ABBREVIATIONS

Abbreviations	Description
AMR	Antimicrobial resistance
ARB	Antibiotic Resistant Bacteria
BLRB	β -Lactam Resistant Bacteria
BLRG	β -lactam resistant gene
MDR	Multidrug Resistant
PDB	Protein Data Bank
MAR Index	Multiple Antibiotic-Resistant Index
MIC	Minimum inhibitory concentration
BLs	β -lactamase
TEM BLs	Temoneria β -lactamase
Km	Michaelis-Menten Constant's
BE	Binding Energy
AAR	Amino Acid Residue
ESBL	Extended Spectrum β -lactamase
SBL	Serine β -lactamase
MBL	Metallo- β -lactamase
NCBI	National Center for Biotechnology
NCMR	National Center for Microbial Resources
BLAST	Basic Local Alignment Tool
nBLAST	Nucleotide Basic Local Alignment Tool
pBLAST	Protein Basic Local Alignment Tool
LACED	Lactamase Engineered Database
MD	Molecular dynamics
RMSD	Root Mean Square Deviation
RMSF	Root Mean Square Fluctuation

SASA	Solvent Accessible Surface Area
Rg	Radius of Gyration
HBO	Hydrogen Bond Occupancy
HBN	Hydrogen Bond Number
MMPBSA	Molecular Mechanics Poisson-Boltzmann Surface Area
WHO	World Health Organisation
ECDC	European Center for Disease Control and Prevention
CLSI	The Clinical & Laboratory Standards Institute
EUCAST	The European Committee on Antimicrobial Susceptibility Testing